The drug, named lenacapavir, targets the structure and function of HIV's capsid protein. It protects people for 6 months with each shot. Unlike mainstay HIV drugs that disrupt viral enzymes by binding ...
Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID-19 and Ebola -- while also minimizing side effects and reducing the odds of ...